Area of research
Nephrology · Hematology
Research interest
Research interests include Medicine, Nephropathy, Internal medicine, Proteinuria, Alternative complement pathway, and Placebo.
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum
Targeting APRIL in the treatment of glomerular diseases
WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Targeting APRIL in the Treatment of IgA Nephropathy
POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?